news
Opaganib reduces COVID-19 mortality by 62 percent in Phase II/III study
Opaganib is the first oral pill-based therapy to significantly reduce mortality outcomes in hospitalised COVID-19 patients.
List view / Grid view
RedHill Biopharma
news
IND submitted for opaganib, potential COVID-19 treatment
RedHill Biopharma has submitted its Investigational New Drug application for its drug opaganib, for the treatment of COVID-19, to the FDA.
news
FDA approves Helicobacter pylori infection treatment
The US FDA has granted approval for the marketing authorisation of Talicia, intended to treat adults with H. pylori infection.
news
RedHill Biopharma enrols last patient in Phase II irritable bowel syndrome trial
26 April 2017 | By Niamh Marriott, Junior Editor
RedHill Biopharma has enrolled the last patient in the Phase II study with Bekinda for the treatment of diarrhoea-predominant irritable bowel syndrome...
news
RedHill Biopharma commences Phase II hepatocellular carcinoma study
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
RedHill Biopharma, will shortly commence a study evaluating yeliva (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), pending final...
news
RedHill Biopharma receives patent approval for MS drug
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
A first Phase III study with RHB-104 for the treatment of Crohn’s disease is currently ongoing, as well as a Phase IIa proof-of-concept study for the treatment of MS...
news
Last patient visit in Phase IIa study with RHB-104 for multiple sclerosis
3 August 2016 | By RedHill Biopharma Ltd.
The last patient visit has been completed in the Phase IIa study evaluating RHB-104 in patients treated for relapsing-remitting multiple sclerosis (RRMS)...
news
RedHill Biopharma has positive results with RHB-104 for multiple sclerosis
1 August 2016 | By RedHill Biopharma Ltd.
RHB-104 for relapsing-remitting multiple sclerosis show positive safety and efficacy signals after the 24-week treatment period ...
news
Positive results for Yeliva in Phase I advanced solid tumour study
4 July 2016 | By Victoria White, Digital Content Producer
Yeliva is a first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor with anticancer and anti-inflammatory activities...
news
First patients dosed in Bekinda IBS-D trial
22 June 2016 | By Victoria White, Digital Content Producer
The first patients have been dosed in a Phase II clinical study with RedHill Biopharma’s Bekinda 12 mg for diarrhoea-predominant irritable bowel syndrome...
news
RedHill Biopharma announces positive FDA meeting on RHB-105
21 April 2016 | By Victoria White, Digital Content Producer
RedHill Biopharma has concluded a positive Type B Meeting with the FDA regarding the path to marketing approval of RHB-105...
news
Redhill initiates Phase II study of Bekinda in IBS-D
12 April 2016 | By Victoria White, Digital Content Producer
The randomised, double-blind Phase II clinical study is designed to evaluate the safety and efficacy of Bekinda 12 mg in patients suffering from IBS-D...
news
Encouraging top-line interim results for RHB-104 in RRMS
5 April 2016 | By Victoria White
RedHill has announced encouraging top-line interim results from its CEASE-MS study of RHB-104 in patients with relapsing-remitting multiple sclerosis...
news
Positive results from Phase III study of RHB-105 for H. pylori infection
10 March 2016 | By Victoria White
The ERADICATE Hp Phase III study was intended to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed H. pylori bacterial infection...
news
RedHill Biopharma and IZI enter RP101 collaboration
8 February 2016 | By Victoria White
The research collaboration will test RP101 in preclinical oncology models in combination with standard-of-care chemotherapies to support existing Phase I and Phase II clinical data...
